344 related articles for article (PubMed ID: 37438589)
1. Practical recommendations for using ctDNA in clinical decision making.
Cohen SA; Liu MC; Aleshin A
Nature; 2023 Jul; 619(7969):259-268. PubMed ID: 37438589
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Naidoo M; Piercey O; Tie J
Curr Oncol Rep; 2021 Nov; 23(12):140. PubMed ID: 34735665
[TBL] [Abstract][Full Text] [Related]
4. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA for clinicians: current and future clinical applications.
Thompson MK; Gale D; Brenton JD
Clin Radiol; 2021 Oct; 76(10):737-747. PubMed ID: 34389159
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
7. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Turner NC; Swift C; Jenkins B; Kilburn L; Coakley M; Beaney M; Fox L; Goddard K; Garcia-Murillas I; Proszek P; Hall P; Harper-Wynne C; Hickish T; Kernaghan S; Macpherson IR; Okines AFC; Palmieri C; Perry S; Randle K; Snowdon C; Stobart H; Wardley AM; Wheatley D; Waters S; Winter MC; Hubank M; Allen SD; Bliss JM;
Ann Oncol; 2023 Feb; 34(2):200-211. PubMed ID: 36423745
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
Lakhotia R; Roschewski M
Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
[TBL] [Abstract][Full Text] [Related]
10. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
[TBL] [Abstract][Full Text] [Related]
16. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
[TBL] [Abstract][Full Text] [Related]
17. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer.
Kim YW; Kim YH; Song Y; Kim HS; Sim HW; Poojan S; Eom BW; Kook MC; Joo J; Hong KM
Exp Mol Med; 2019 Aug; 51(8):1-10. PubMed ID: 31395853
[TBL] [Abstract][Full Text] [Related]
18. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
19. Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors.
Coakley M; Garcia-Murillas I; Turner NC
Clin Cancer Res; 2019 Oct; 25(20):6026-6034. PubMed ID: 31088829
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer.
Akashi K; Sakai T; Fukuoka O; Saito Y; Yoshida M; Ando M; Ito T; Murakami Y; Yamasoba T
Sci Rep; 2022 Jan; 12(1):572. PubMed ID: 35022425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
